Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to assess the toxicity and the rate of complete and overall
response using fludarabine, rituximab, and alemtuzumab to treat patients with B-chronic
lymphocytic leukemia or small lymphocytic leukemia who have received previous treatment.